Investigation of Thermal Injury on Intestinal Permeability in Both Thermal Injury and Healthy Participants

Inclusion Criteria: For Healthy participants: * Males or females must be greater than or equal to 18 years of age at the time of signing informed consent. * Participants who are healthy as determined by the investigator following medical evaluation including medical history, physical examination, and laboratory tests. * A female participant is eligible to participate if she is not pregnant (negative pregnancy testing at screening or Day 1 as needed) and not breastfeeding. * Capable of giving signed informed consent. For Thermally injured participants: * Participants must be greater than or equal to 18 years of age. * Participants who have sustained a burn (thermal injury) with a Total Burn Surface Area (TBSA) greater than or equal to 15 percent. * Admission to the burn center (study site) less than or equal to 24 hours following injury. * Able to take enteral fluids either orally or via a nasogastric tube (depends on facial burn damage). * A female participant is eligible to participate if she is not pregnant (negative pregnancy testing at study entry) and not breastfeeding. Exclusion Criteria For Healthy participants: * Healthy participants are excluded from this study if they are receiving anti-coagulation therapy. * Pregnancy or breastfeeding. * A body mass index greater than 34 kilogram per meter square (kg/m\^2). * An active history of alcohol dependency. * History of sensitivity to any of the STM, or components thereof or a history of drug or other allergy that, in the opinion of the Investigator and/or GlaxoSmithKline (GSK) Medical Monitor, contraindicates their participation. * A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody and confirmatory Hepatitis C Polymerase Chain Reaction (PCR) result within 3 months of screening. * A positive pre-study urine drug/alcohol screen. * A positive test for Human Immuno-deficiency Virus (HIV) antibody. * Participants unable to swallow large capsules (the capsules will be shown to participants at screening). * Galactosaemia or severe lactose intolerance. * Use of an antibiotic 2 weeks prior to study start (administration of the STM). * Gastroenteritis in the 2 weeks prior to study start (administration of the STM). For thermally injured participants: * Chemical or electrical burn. * Multiple traumatic injuries with an Injury Severity Score (ISS) more than or equal to 16. * Participants received substantial undocumented management prior to arrival at the study site (burn center) e.g. from paramedics or in a local accident and emergency department. * Systemic corticoidsteroid use. * Intravenous (IV) Mannitol use. * HIV infection. * Viral Hepatitis B or C infection. * Gastrointestinal disease (e.g. inflammatory bowel disease) which may affect intestinal permeability. * Previous bowel resection (e.g. hemicolectomy, small bowel resection). * Galactosaemia or severe lactose intolerance. * Bowel obstruction. * Renal dysfunction requiring renal replacement therapy (end-stage renal failure prior to thermal injury). * Active autoimmune disease and receiving immunomodulatory therapy e.g. rheumatoid arthritis anti-Tumor Necrosis Factor (TNF). * Active chemotherapy for cancers or immunoremittive therapies (prednisolone, Adalimumab) within 60 days of thermal injury. * Premorbid conditions of malignancy currently under treatment. * Previous bilateral lower extremity amputation. * Decision not to treat the participant due to futility.